

Protalix BioTherapeutics, Inc.  
Form 8-K  
December 01, 2009

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
Date of Report (Date of earliest event reported): December 1, 2009 (November 30, 2009)**

**Protalix BioTherapeutics, Inc.**  
(Exact name of registrant as specified in its charter)

**Florida**  
(State or other jurisdiction  
of incorporation)

**000-33357**  
(Commission File Number)

**65-0643773**  
(I.R.S. Employer  
Identification No.)

**Snunit Street  
Science Park  
POB 455 Carmiel, Israel**  
(Address of principal executive offices)

**20100**  
(Zip Code)

Registrant's telephone number, including area code: **+972-4-988-9488**

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01. Entry into a Material Definitive Agreement**

On December 1, 2009, Protalix BioTherapeutics, Inc. (the Company ) and Pfizer Inc. ( Pfizer ) announced that the Company s wholly owned subsidiary, Protalix Ltd. ( Protalix ), had entered into an Exclusive License and Supply Agreement, dated November 30, 2009, with Pfizer (the License Agreement ), to develop and commercialize taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD) in development for the potential treatment of Type 1 Gaucher s disease. Under the terms of the License Agreement, Pfizer will receive exclusive worldwide licensing rights for the commercialization of taliglucerase alfa, while Protalix will retain the exclusive commercialization rights in Israel. Pfizer will make an upfront payment of \$60 million to Protalix. Protalix is eligible to receive additional regulatory milestone payments of up to \$55 million. In addition, Pfizer and Protalix will share future revenues and expenses for the development and commercialization of taliglucerase alfa on a 60 percent/40 percent basis, respectively.

The License Agreement includes mutual non-competition covenants for a specified period and subject to specified exceptions, as well as customary termination provisions.

The Company has agreed to unconditionally guarantee the obligations and liabilities of Protalix under the License Agreement.

**Item 8.01. Other Events**

On December 1, 2009, the Company and Pfizer Inc. issued a press release announcing the entry into the License Agreement. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

**Item 9.01. Financial Statements and Exhibits**

**(d) Exhibits**

99.1 Press Release dated December 1, 2009

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Protalix BioTherapeutics, Inc.**

Date: December 1, 2009

By: /s/ David Aviezer  
David Aviezer, Ph.D.  
President and Chief Executive Officer

---

Exhibit Index

Number	Description
99.1	Press Release dated December 1, 2009